No profile data available.
AC Immune SA (ACIU) is a healthcare company in the brain and nerve treatment drugs industry, based in Lausanne, Switzerland, with about 90 full-time employees.
It reported revenue of 3.57 million CHF for fiscal year 2025, down 86.9% from fiscal year 2024, and net income of -70.45 million CHF. Its market capitalization was $269.45 million as of October 5, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 5, 2026.
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding.
AC Immune SA reported 3.57 million CHF in revenue for fiscal year 2025, down 86.9% from 27.31 million CHF in fiscal year 2024.
$269.45 million as of October 5, 2026.
Listed companies of a similar size in the same industry (brain and nerve treatment drugs) include Larimar Therapeutics, Inc. (LRMR), Vanda Pharmaceuticals Inc. (VNDA), Inhibikase Therapeutics, Inc. (IKT), Alector, Inc. (ALEC).